Table 5 Incidence and duration of skin rash, and administered treatments

Incidence proportion of skin rash (n, %)¹

356 (19.97%)

182 (28.89%)

131 (28.85%)

Incidence rate of skin rash (per patient year)¹

Patient years at risk (patient years)

3614.53

837.02

804.78

Incidence rate (per 100 patient years)

9.85

21.74

16.28

95% CI (lower–upper)

8.88–10.93

18.80–25.14

13.72–19.32

Duration of skin rash (days)

n

356

182

131

Mean (SD)

138.30 (222.11)

120.50 (175.83)

134.10 (249.52)

Median

42 (1:1401)

42 (1:1196)

29 (1:1881)

IQR (Q1:Q3)

127 (28,155)

119 (28,147)

103 (28:131)

Missing

1427

448

323

Drugs used for treatment of prostate cancer between index date (inclusive) and the first onset of skin rash (exclusive) (n, %)²

n

356

182

131

Goserelin

112 (31.46%)

44 (24.18%)

24 (18.32%)

Median duration (days)

591

459

590

Leuprorelin acetate

156 (43.82%)

57 (31.32%)

37 (28.24%)

Median duration (days)

468

336

430

Degarelix

36 (10.11%)

42 (23.08%)

43 (32.82%)

Median duration (days)

149

251

239

Flutamide

70 (19.66%)

32 (17.58%)

20 (15.27%)

Median duration (days)

142

125

81

Bicalutamide

148 (41.57%)

50 (27.47%)

84 (64.12%)

Median duration (days)

340

151

322

Enzalutamide

72 (20.22%)

32 (17.58%)

10 (7.63%)

Median duration (days)

295

237

275

Apalutamide

12 (3.37%)

2 (1.10%)

2 (1.53%)

Median duration (days)

112

93

279

Abiraterone Acetate (plus prednisolone)

38 (10.67%)

28 (15.38%)

17 (12.98%)

Median duration (days)

146

139

171

Darolutamide

0 (0.00%)

1 (0.55%)

0 (0.00%)

Median duration (days)

150

237

237

Docetaxel

62 (17.42%)

56 (30.77%)

16 (12.21%)

Median duration (days)

177

153

164

Cabazitaxel

14 (3.93%)

19 (10.44%)

3 (2.29%)

Median duration (days)

120

84

62

Radium-223

0 (0.00%)

5 (2.75%)

1 (0.76%)

Median duration (days)

0

139

139